All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Key considerations when preparing patients with ALL for CAR T-cell therapy
By Louise Niven
Key considerations when preparing patients with ALL for CAR T-cell therapy
During the ALL Hub Steering Committee meeting, André Baruchel chaired a discussion on “What are the key considerations when preparing patients with ALL for CAR T-cell therapy ?”, featuring Andrea Biondi, Anita Rijneveld, and José María Ribera.
The discussion topics included:
-
Key considerations when selecting patients: stable disease, degree of antigen expression, burden of bone marrow disease, and number of circulating tumor blasts
-
Bridging therapy and lymphodepletion considerations
-
The impact of prior exposure to blinatumomab and inotuzumab on CAR T-cell outcomes
-
Indications for the use of tisagenlecleucel in pediatric ALL
-
Indications for the use of brexucabtagene autoleucel in adult ALL
Key considerations when preparing patients with ALL for CAR T-cell therapy
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox